Valchlor prices near Virginia Beach, VA
Lowest: $8,212.55 Highest: $8,730.64
What is Valchlor?
USES: This medication is used on the skin to treat a certain type of cancer (cutaneous T-cell lymphoma). Mechlorethamine belongs to a class of drugs known as alkylating agents. It works by slowing or stopping the growth of cancer cells that cause the skin condition.
How to take Valchlor
HOW TO USE: Read the Medication Guide provided by your pharmacist before you start using this medication and each time you get a refill. If you have any questions, ask your doctor or pharmacist. Use this medication as directed by your doctor, usually once a day. After taking this medication out of the refrigerator, apply it within 30 minutes, and be sure to return it to the refrigerator right after each use. Apply a small amount of medication to completely dry skin at least 4 hours before or 30 minutes after showering or washing. Let the treated area(s) dry for 5 to 10 minutes before covering with clothing. You may apply moisturizers to the treated area(s) 2 hours before or 2 hours after applying mechlorethamine. If someone helps you apply this medication, they must wear disposable gloves. If you are applying it to yourself, you can wear disposable gloves but you do not have to. After applying, wash your hands right away, even if you have worn gloves (see also Side Effects section). Safely throw away any used gloves in the trash. Do not cover the treated area with tight dressings or plastic bandages. Ask your doctor whether you may cover the treated area loosely with gauze. Avoid getting this medication in or around the eyes or eyelids. It can cause pain, burns, blurred vision, and even blindness. Also, do not apply this medication inside the nose or mouth. If you accidentally get this medication in the eyes, rinse for at least 15 minutes with plenty of water, normal saline, or an eye wash solution and get medical help right away (including exam by an eye doctor). If you get this medication in the nose or mouth, rinse for at least 15 minutes with plenty of water and tell the doctor right away. Use this medication exactly as prescribed. Do not increase your dose or use this drug more often than directed. Your condition will not improve any faster, and your risk of side effects will increase. This medication is flammable until dry. Let the medication dry before smoking or going near an open flame. Tell your doctor if your condition does not get better or if it gets worse.
What if I miss a dose of Valchlor?
MISSED DOSE: If you miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Use your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store in the refrigerator, but away from food. With clean hands, put this medication back in the original box and return it to the refrigerator right after each use. Keep all medications away from children and pets. Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Use/discard this medication within 60 days. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Side Effects of Valchlor
SIDE EFFECTS: Skin irritation, itching, blisters, burning, redness, pain, swelling, tenderness, or darkening of skin where you have applied medication may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly. Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects. Tell your doctor right away if you have any serious side effects, including: easy bruising/bleeding, signs of infection (such as skin ulcers/pus, fever, chills). Very rarely, people who are treated with or who have had contact with this medication have developed other skin cancers. Tell your doctor right away if you, or someone who has helped you apply this medication, notice any new skin lesions or unusual skin changes. Ask your doctor for details. A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing. This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist. In the US - Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch. In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Interactions with Valchlor
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.
PRECAUTIONS: Before using mechlorethamine, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details. Before using this medication, tell your doctor or pharmacist your medical history, especially of: red/irritated/infected/open sores on skin. Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products). Tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while using mechlorethamine. Mechlorethamine may harm an unborn baby. If you become pregnant, talk to your doctor right away about the risks and benefits of this medication. It is unknown if this medication passes into breast milk. Because of the possible risk to the infant, breast-feeding while using this drug is not recommended. Consult your doctor before breast-feeding.
Conditions Commonly Treated by Valchlor
Prescription prices may vary from pharmacy to pharmacy and are subject to change. The pricing estimates given are based on the most recent information available and may change based on when you actually fill your prescription at the pharmacy. The day supply is based upon the average dispensing patterns or the specific drug and strength. The Program, as well as the prices and the list of covered drugs, can be modified at any time without notice.
Blog Posts Related to Valchlor
Are you one of the many people in the United States planning to enjoy a smoke-free 2019? A new year comes with the promise of a clean slate and the opportunity to make resolutions to improve your quality of life, leaving you a healthier, stronger and happier person. A YouGov NY poll conducted last...
The US Food and Drug Administration (FDA) has released the first of two new pieces of draft guidance that may eventually enable e-cigarette manufacturers to apply for regulated drug status for their products.
FDA Commissioner Scott Gottlieb, MD, said there is “no greater impact we can...
Streamlining the process of bringing biosimilars to market is one of the keys to facilitating innovation and reducing healthcare costs, according to US Food and Drug Administration (FDA) Commissioner Scott Gottlieb.
Speaking at the Brookings Institution on the release of the FDA’s...
Fulphila (pegfilgrastim-jmdb) is the first biosimilar to Neulasta (pegfilgrastim) to gain approval from the US Food and Drug Administration (FDA). The Mylan GmbH medicine was approved as a treatment to reduce the risk of infection as suggested by febrile neutropenia (fever caused by a lack of...
Among white and Hispanic people born after 1965, rates of lung cancer are now higher in women than men, according to researchers from the American Cancer Society and National Cancer Institute.
The study, published last month in the New England Journal of Medicine, revealed an overall decline...
The US Food and Drug Administration (FDA) has approved the protein kinase inhibitor Tagrisso (osimertinib) as a first-line treatment option for certain patients with metastatic non-small cell lung carcinoma (NSCLC). Earlier this month, AstraZeneca presented new data from a Phase III FLAURA trial...
The US Food and Drug Administration (FDA) has expanded the approval of Imfinzi (durvalumab) to provide a therapy to slow the progression of cancer in certain patients with non-small cell lung cancer (NSCLC). AstraZeneca first gained accelerated FDA approval for Imfinzi in May 2017.
Imfinzi is an...
More than four in ten (42 percent) of cancer cases in the United States are linked to risk factors associated with cancer, such as smoking, obesity, poor diet, ultraviolet radiation and physical inactivity, according to a new study conducted by the American Cancer Society. The results of the...
Around 49 million American adults were still using tobacco products in 2015, according to new data published by the Centers for Disease Control and Prevention (CDC) and the US Food and Drug Administration’s (FDA) Center for Tobacco Products.
The Morbidity and Mortality Weekly Report...
The US Food and Drug Administration (FDA) has granted breakthrough therapy (BTD) designation to the AstraZeneca drug Tagrisso (osimertinib). It is the sixth such designation granted to AstraZeneca oncology medicine since 2014. Tagrisso received BTD for first-line treatment of patients with...
The US Food & Drug Administration's (FDA) decision to approve a medication to treat patients whose cancer has a specific genetic feature, or biomarker, has been hailed as an "important first" in the fight against the disease. Keytruda (pembrolizumab) is a monoclonal antibody already in use to...
Non-small cell lung cancer (NSCLC) patients have a new treatment available following the US Food & Drug Administration's (FDA's) approval of Alunbrig (brigatinib). The Takeda Pharmaceuticals medication received Accelerated Approval for treatment of patients with anapestic lymphoma...
The US Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) as a treatment for certain adult patients with classical Hodgkin lymphoma (cHL). Under the latest approval, the Seattle Genetics drug is indicated for use in combination with chemotherapy as a treatment for...
The US Food and Drug Administration (FDA) has issued a statement clarifying its position on Keytruda (pembrolizumab) after scientists monitoring studies of the drug found an excess of deaths among patients given the drug in combination with certain other medicines.
Currently, Keytruda is...
Patients in the United States who suffer from mantle cell lymphoma have a new treatment option available following the US Food and Drug Administration's (FDA's) decision to grant accelerated approval to Calquence (acalabrutinib). The AstraZeneca Pharmaceuticals drug was granted Priority Review,...
The US Food and Drug Administration (FDA) has given the nod to Yescarta (axicabtagene ciloleucel), the first cell-based gene therapy granted approval for the treatment of certain types of non-Hodgkin lymphoma (NHL) and only the second gene therapy to gain FDA approval.
The drug is indicated for...
A new treatment will soon be available for adults with relapsed follicular lymphoma, a slow-growing form of non-Hodgkin lymphoma, following the US Food and Drug Administration's (FDA) approval of Aliqopa (copanlisib). The drug was granted Accelerated Approval as it fills an unmet medical need....
Americans have been urged to take precautions to protect against ultraviolet (UV) radiation and skin cancer during the hotter months of the year. In a statement issued by the US Food and Drug Administration (FDA), FDA Commissioner Scott Gottlieb, MD, highlighted the dangers and prevalence of skin...
Pharmaceutical manufacturer Sanofi has announced that the US Food and Drug Administration (FGA) has granted Breakthrough Therapy Designation to Cemiplimab (REGN2810) as a treatment for adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable...
Similar Drugs To Valchlor & Other Other Topical Antineoplastics